Earendil LabsIn Development
Two bispecific antibodies licensed exclusively to Sanofi for autoimmune and inflammatory bowel disease. HXN-1002 targets α4β7 and TL1A for moderate-to-severe ulcerative colitis and Crohn's disease. HXN-1003 targets TL1A and IL-23 and has shown synergistic activity in preclinical colitis and skin-inflammation models.
Latest update Sep 18, 2026
01
Out-licensed to Sanofi in April 2025. Sanofi holds exclusive worldwide rights and is responsible for development. No Sanofi-run clinical start has been announced as of September 18, 2026. Still listed on Earendil's IBD pipeline table.
02
03
Announced next steps from Earendil Labs that mention HXN-1002 and HXN-1003 (Sanofi).
Not disclosed
The April 2025 license put two bispecifics in Sanofi's hands. As of September 18, 2026 Sanofi has not announced a first-in-human study for either asset. A posted trial, an IND, or a Sanofi pipeline listing is the next hard signal that the first deal is more than an upfront payment.
04
Earendil's foundational protein-AI stack for antibody sequence design, structure and epitope prediction, biophysical-property scoring and closed-loop optimization, paired with high-throughput wet-lab validation. The public scientific ancestor is OmegaFold, Helixon's 2022 single-sequence structure predictor.
A half-life extended anti-TL1A monoclonal antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease, formulated at high protein concentration for subcutaneous injection.
A recombinant humanized biparatopic antibody against two epitopes on TSLP that is designed to block both units of the heterodimeric TSLP receptor (TSLPR/CRLF2 and IL-7Rα). High-concentration subcutaneous formulation. Aimed at asthma, COPD and other TSLP-driven inflammatory diseases.
A preclinical oncology set listed on Earendil's pipeline page: CDH17 dual-payload ADC (HXN-2001), CEACAM5/CDH17 TCE and ADC, GUCY2C TCE, DLL3 TCE and dual-payload ADC, B7-H3 ADC, TROP2/PD-L1 and EGFR/PD-L1 bispecific ADCs, and a PD-1/IL-15 fusion protein. February 2026 WuXiTecan-2 license is meant to supply payload-linkers for a subset of these ADCs.
05
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
Oklo
Oklo's isotope business combines the Idaho Radiochemistry Laboratory, a planned pilot reactor in Texas, and a future multi-reactor foundry to supply critical medical, industrial, research, defense, and space isotopes.
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.